Update on Funding & Suspension of Trading

Trellus Health PLC

08 May 2026

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Trellus Health plc

("Trellus Health" or the "Company") 

Update on Funding

&

Suspension of Trading

Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programmes and value-based solutions to manage complex chronic conditions, stated on 13 April 2026 that it had reduced its monthly cash burn to an average of c. $300k as of March 2026 and that, with a contract renewal, and a loan from a co-founder, it expected its cash runway to extend into May 2026.

The Board remains supportive of the Company's commercial strategy and continues to evaluate a range of potential funding options to further extend the Company's cash runway. The Company has further extended its runway until mid-June 2026 through additional cost-saving measures, including further reductions in compensation and the renegotiation of certain vendor contracts amongst other measures.

The Board is, however, mindful that it has not yet been successful in securing long term funding. In addition, although the Convertible Loan Note Facility provided by Alumni Capital LLC remains in place, utilisation continues to be constrained by current market conditions.

Consequently, the Board has engaged corporate restructuring advisers to protect stakeholders' interests, and the Board is now evaluating all options including the sale of Trellus Health Inc., the Company's US subsidiary. Due to the ongoing uncertainty regarding the Company's financial position, its current limited working capital and the circumstances noted above, the Company has requested that its shares are suspended from trading on AIM with effect from 7.30 a.m. today.

Further announcements will be made as appropriate.

Enquiries:

Trellus Health plc				https://trellushealth.com/
Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder				Via Walbrook PR
Joy Bessenger, Chief Financial Officer
Singer Capital Markets (Nominated Adviser and Broker)
Philip Davies / Jalini Kalaravy / Samed Ethemi		Tel: [phone] 303/
Walbrook PR	Tel: [phone] or [e-mail]
Lianne Applegarth /			Mob: [phone]/
Alice Woodings					[phone]

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health® integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health® considers its approach to have potential utility and demand across many conditions.

The Company also offers Trellus TrialSet™, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement

The Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com

 

END